GSK795 is primarily researched for its potential therapeutic applications, particularly in the field of immunology and oncology. It is known to inhibit specific enzymes or pathways that play a role in immune responses and cancer progression. In preclinical studies, GSK795 has shown promise in modulating immune cell activity, making it a candidate for treating autoimmune diseases or enhancing anti-tumor immunity. Additionally, its mechanism of action suggests potential use in combination therapies to improve the efficacy of existing cancer treatments. Research is ongoing to explore its full therapeutic potential and safety profile in clinical settings.